Hmscs
Agitation in Dementia
Bernard (Barry) BaumelCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
43 Active assets in the Agitation in Dementia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Risperdal Hannover Medical School | Phase 4 | BBB |
CITALOPRAM Hannover Medical School | Phase 4 | BBB |
Galantamine Hydrobromide Janssen Pharmaceutica N.V., Belgium | Phase 3 | BB |
Namenda Zealand University Hospital | Phase 4 | BB |
Cipralex Ohio State University | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Hmscs is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →